TLP
Tri Locum Partners Portfolio holdings
AUM
$330M
This Quarter Return
+13.78%
1 Year Return
+35.44%
3 Year Return
+388.28%
5 Year Return
–
10 Year Return
–
AUM
$204M
AUM Growth
+$204M
(-35%)
Cap. Flow
-$227M
Cap. Flow
% of AUM
-111.53%
Top 10 Holdings %
Top 10 Hldgs %
69.16%
Holding
65
New
4
Increased
5
Reduced
14
Closed
41
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$12.5M |
| 2 |
Biogen
BIIB
|
$11.9M |
| 3 |
Legend Biotech
LEGN
|
$6.15M |
| 4 |
Scholar Rock
SRRK
|
$3.89M |
| 5 |
argenx
ARGX
|
$3.74M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$103M |
| 2 |
Amgen
AMGN
|
$28.9M |
| 3 |
DexCom
DXCM
|
$24.9M |
| 4 |
SPDR S&P 500 ETF Trust
SPY
|
$19.3M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$8.75M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| 3 | Energy | 0% |
| 4 | Financials | 0% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
AbbVie
ABBV
$372B
| $26M | 11.89% | 167,807 +23,246 | +16% | +$3.6M |
|
|
2
Teva Pharmaceuticals
TEVA
$21.1B
| $18.7M | 8.56% | 1,794,335 -838,558 | -32% | -$8.75M |
|
3
Regeneron Pharmaceuticals
REGN
$61.5B
| $14.1M | 6.43% | 16,012 -3,997 | -20% | -$3.51M |
|
4
GE HealthCare
GEHC
$33.7B
| $13.3M | 6.07% | 171,676 +39,866 | +30% | +$3.08M |
|
|
5
Ascendis Pharma
ASND
$11.8B
| $12.5M | 5.73% | +99,550 | New | +$12.5M |
|
|
AVDL
6
Avadel Pharmaceuticals
AVDL
$1.43B
| $11.9M | 5.42% | 839,933 -143,669 | -15% | -$2.03M |
|
|
7
Biogen
BIIB
$19.4B
| $11.9M | 5.42% | +45,814 | New | +$11.9M |
|
|
CTLT
8
DELISTED
CATALENT, INC.
CTLT
| $11.8M | 5.38% | 261,797 -24,202 | -8% | -$1.09M |
|
9
Axsome Therapeutics
AXSM
$6.05B
| $10.4M | 4.76% | 130,738 -11,772 | -8% | -$937K |
|
10
Xenon Pharmaceuticals
XENE
$2.98B
| $10.4M | 4.75% | 225,564 +53,809 | +31% | +$2.48M |
|
|
11
argenx
ARGX
$43.6B
| $9.2M | 4.21% | 24,182 +9,836 | +69% | +$3.74M |
|
12
Natera
NTRA
$23.1B
| $8.89M | 4.06% | 141,847 -132,948 | -48% | -$8.33M |
|
|
13
Legend Biotech
LEGN
$6.41B
| $6.15M | 2.81% | +102,215 | New | +$6.15M |
|
14
Madrigal Pharmaceuticals
MDGL
$9.76B
| $5.91M | 2.7% | 25,524 -8,237 | -24% | -$1.91M |
|
|
VRNA
15
Verona Pharma
VRNA
$9.16B
| $5.83M | 2.66% | 293,112 -24,964 | -8% | -$496K |
|
|
16
Praxis Precision Medicines
PRAX
$958M
| $5.54M | 2.53% | 248,761 -4,607,022 | -95% | -$103M |
|
17
Astria Therapeutics
ATXS
$349M
| $4.17M | 1.91% | 542,945 -55,183 | -9% | -$424K |
|
18
AstraZeneca
AZN
$248B
| $3.96M | 1.81% | 58,787 +14,553 | +33% | +$980K |
|
|
19
Scholar Rock
SRRK
$3.14B
| $3.89M | 1.78% | +207,147 | New | +$3.89M |
|
20
Arcturus Therapeutics
ARCT
$462M
| $3.48M | 1.59% | 110,470 -98,416 | -47% | -$3.1M |
|
21
Immatics
IMTX
$619M
| $2.9M | 1.33% | 275,482 -29,492 | -10% | -$311K |
|
22
MoonLake Immunotherapeutics
MLTX
$3.54B
| $2.87M | 1.31% | 47,604 -5,696 | -11% | -$344K |
|
23
Femasys
FEMY
$11.6M
| $35.2K | 0.02% | 36,150 -40,455 | -53% | -$39.4K |
|
24
Antero Midstream
AM
$8.51B
| – | – | -13,448 | Closed | -$161K |
|
|
25
Amgen
AMGN
$155B
| – | – | -107,480 | Closed | -$28.9M |
|